Janssen Research & Development has submitted a Supplemental New Drug Application to the FDA for Olysio (simeprevir) in combination with...
NICE (The National Institute for Health and Care Excellence) draft guidance recommends Olysio (simeprevir) from Janssen Cilag, in combination with...
Janssen R&D Ireland (Janssen) today announced the presentation of additional data for the NS3/4A protease inhibitor OLYSIO® (simeprevir) at the...
The FDA has approved Olysio (simeprevir), from Janssen R&D, for the treatment of chronic Hepatitis C infection as part of...
The FDA has approved Olysio (simeprevir) in combination with Sovaldi (sofosbuvir), from Medivir and Janssen, as an all-oral, interferon- and...
New Phase III data for the once-daily Olysio (simeprevir), from Medivir, for the treatment of patients with Hepatitis C, show...
Janssen Sciences has announced results for its Hepatitis C treatment Olysio plus Sovaldi (simeprevir plus sofosbuvir) in Genotype 1 HCV...
Medivir has announced that results from the Phase II COSMOS clinical study were published in The Lancet, demonstrating that 92...
Janssen-Cilag has announced that Olysio (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of...
In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found indications and...